{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:50:53Z","timestamp":1787161853999,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007311","name":"Cleveland Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007311","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.idc.2020.02.011","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T02:02:46Z","timestamp":1589940166000},"page":"413-423","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Mycobacterial Infections Potentiated by Biologics"],"prefix":"10.1016","volume":"34","author":[{"given":"Cassandra","family":"Calabrese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.idc.2020.02.011_bib1","first-page":"1","article-title":"2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.idc.2020.02.011_bib2","first-page":"53","article-title":"The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment","volume":"52","author":"Listing","year":"2013","journal-title":"Rheumatol"},{"key":"10.1016\/j.idc.2020.02.011_bib3","series-title":"Global tuberculosis report","author":"World Health Organization (WHO)","year":"2019"},{"key":"10.1016\/j.idc.2020.02.011_bib4","first-page":"ii61","article-title":"Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents","volume":"61","author":"Furst","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.idc.2020.02.011_bib5","first-page":"1932","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.idc.2020.02.011_bib6","first-page":"1098","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor \u03b1\u2013neutralizing agent","volume":"345","author":"Joseph","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.idc.2020.02.011_bib7","first-page":"37","article-title":"Mycobacterial diseases and antitumor necrosis factor therapy in USA","volume":"72","author":"Winthrop","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.idc.2020.02.011_bib8","first-page":"1884","article-title":"Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry","volume":"60","author":"Tubach","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.idc.2020.02.011_bib9","first-page":"522","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.idc.2020.02.011_bib10","first-page":"706","article-title":"Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers","volume":"34","author":"Seong","year":"2007","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.idc.2020.02.011_bib11","first-page":"2218","article-title":"Incidence of tuberculosis among Korean patients with ankylosing spondylitis who are taking tumor necrosis factor blockers","volume":"38","author":"Kim","year":"2011","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.idc.2020.02.011_bib12","first-page":"1942","article-title":"Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety assessment of biologic ThERapy (SABER) study","volume":"73","author":"Baddley","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.idc.2020.02.011_bib13","first-page":"47","article-title":"Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance","volume":"91","author":"Cantini","year":"2014","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.idc.2020.02.011_bib14","first-page":"1261","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists","volume":"38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2020.02.011_bib15","first-page":"486","article-title":"Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity","volume":"194","author":"Saliu","year":"2006","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.idc.2020.02.011_bib16","first-page":"1643","article-title":"Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis","volume":"195","author":"Plessner","year":"2007","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.idc.2020.02.011_bib17","first-page":"1872","article-title":"Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies","volume":"53","author":"Souto","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.idc.2020.02.011_bib18","first-page":"2148","article-title":"Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients","volume":"70","author":"Koike","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.idc.2020.02.011_bib19","first-page":"e26938","article-title":"Functional correlations of pathogenesis-driven gene expression signatures in tuberculosis","volume":"6","author":"Maertzdorf","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.idc.2020.02.011_bib20","first-page":"234","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"10.1016\/j.idc.2020.02.011_bib21","first-page":"1133","article-title":"Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.idc.2020.02.011_bib22","first-page":"787","article-title":"Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program","volume":"40","author":"Weinblatt","year":"2013","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.idc.2020.02.011_bib23","first-page":"1096","article-title":"Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"67","author":"Schiff","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.idc.2020.02.011_bib24","article-title":"Long-term safety of rituximab in rheumatoid arthritis: analysis from the SUNSTONE registry","author":"Winthrop","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.idc.2020.02.011_bib25","first-page":"909","article-title":"Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"70","author":"Buch","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.idc.2020.02.011_bib26","first-page":"7222","article-title":"Cells moderate inflammatory progression and enhance bacterial containment upon pulmonary challenge with Mycobacterium tuberculosis","volume":"178","author":"Maglione","year":"2007","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.idc.2020.02.011_bib27","first-page":"5575","article-title":"The effect of bacille Calmette-Gu\u00e9rin vaccine on tuberculin reactivity in indigenous children from communities with high prevalence of tuberculosis","volume":"26","author":"Araujo","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.idc.2020.02.011_bib28","first-page":"1063","article-title":"Evaluating indeterminate interferon-\u03b3-release assay results in patients with chronic inflammatory diseases receiving immunosuppressive therapy","volume":"67","author":"Calabrese","year":"2015","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.idc.2020.02.011_bib29","first-page":"111","article-title":"Official American Thoracic Society\/Infectious Diseases Society of America\/Centers for Disease Control and Prevention Clinical Practice Guidelines: diagnosis of tuberculosis in adults and children","volume":"64","author":"Lewinsohn","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2020.02.011_bib30","first-page":"43","article-title":"The risk and prevention of tuberculosis: screening strategies to detect latent tuberculosis among rheumatoid arthritis patients who use biologic therapy","volume":"8","author":"Winthrop","year":"2010","journal-title":"Int J Adv Rheumatol"},{"key":"10.1016\/j.idc.2020.02.011_bib31","first-page":"2102","article-title":"Comparison of two gamma interferon release assays and tuberculin skin testing for tuberculosis screening in a cohort of patients with rheumatic diseases starting anti-tumor necrosis factor therapy","volume":"18","author":"Vassilopoulos","year":"2011","journal-title":"Clin Vaccin Immunol"},{"key":"10.1016\/j.idc.2020.02.011_bib32","first-page":"1271","article-title":"Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment","volume":"35","author":"Vassilopoulos","year":"2008","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.idc.2020.02.011_bib33","first-page":"417","article-title":"Screening of latent tuberculosis infection by interferon-\u03b3 release assays in rheumatic patients: a systemic review and meta-analysis","volume":"35","author":"Ruan","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.idc.2020.02.011_bib34","first-page":"1757","article-title":"You can\u2019t always get what you want, but if you try sometimes (with two tests--TST and IGRA--for tuberculosis) you get what you need","volume":"71","author":"Winthrop","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.idc.2020.02.011_bib35","first-page":"62","article-title":"Interferon-gamma release assays for tuberculosis screening of healthcare workers: a systematic review","volume":"67","author":"Zwerling","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.idc.2020.02.011_bib38","first-page":"1001","article-title":"One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis","volume":"380","author":"Swindells","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.idc.2020.02.011_bib39","first-page":"2968","article-title":"Tuberculosis associated with therapy against tumor necrosis factor alpha","volume":"52","author":"Winthrop","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.idc.2020.02.011_bib40","first-page":"791","article-title":"French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA and treated with TNF blockers","volume":"62","author":"Mariette","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.idc.2020.02.011_bib41","first-page":"800","article-title":"BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-a treatment British","volume":"60","author":"Ormerod","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.idc.2020.02.011_bib42","first-page":"173","article-title":"Paradoxical anti-TNF-associated TB worsening: frequency and factors associated with IRIS","volume":"83","author":"Rivoisy","year":"2016","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.idc.2020.02.011_bib43","first-page":"258","article-title":"A\u00a0paradoxical treatment for a paradoxical condition: infliximab use in three cases of mycobacterial IRIS","volume":"62","author":"Hsu","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2020.02.011_bib44","first-page":"e99260","article-title":"Nontuberculous mycobacterial infection is associated with increased respiratory failure: a nationwide cohort study","volume":"9","author":"Yeh","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.idc.2020.02.011_bib45","first-page":"642","article-title":"Population-based incidence of pulmonary nontuberculous mycobacterial disease in Oregon 2007 to 2012","volume":"12","author":"Henkle","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.idc.2020.02.011_bib46","first-page":"1738","article-title":"Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network","volume":"46","author":"Winthrop","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.idc.2020.02.011_bib47","first-page":"29443","article-title":"Risk factors and outcomes of nontuberculous mycobacterial disease among rheumatoid arthritis patients: a case-control study in a TB endemic area","volume":"6","author":"Liao","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.idc.2020.02.011_bib48","first-page":"1505","article-title":"Mycobacterium abscessus infection during ustekinumab treatment in Crohn\u2019s disease: a case report and review of the literature","volume":"12","author":"Shim","year":"2018","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.idc.2020.02.011_bib49","first-page":"977","article-title":"Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease","volume":"182","author":"Winthrop","year":"2010","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552020300131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891552020300131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:16:25Z","timestamp":1760195785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891552020300131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0891552020300131"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2020.02.011","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mycobacterial Infections Potentiated by Biologics","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2020.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}